董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Samit Hirawat | 男 | Director | 58 | 未披露 | 未持股 | 2026-09-21 |
| Mary Tagliaferri | 女 | Director | 60 | 未披露 | 3.33 | 2026-09-21 |
| William Rastetter | 男 | Director | 78 | 未披露 | 25.78 | 2026-09-21 |
| Thomas Miller | 男 | Chief Executive Officer and Director | 48 | 90.62万美元 | 139.39 | 2026-09-21 |
| R. Jacob Vogelstein | 男 | Director | 48 | 未披露 | 419.66 | 2026-09-21 |
| Frederick Manby | 男 | Chief Technology Officer and Director | 54 | 70.71万美元 | 196.44 | 2026-09-21 |
| Shalini Sharp | 女 | Director | 51 | 未披露 | 未持股 | 2026-09-21 |
| Samit Hirawat | 男 | Director | 58 | 未披露 | 未持股 | 2026-09-21 |
| Evan Rachlin | 男 | Director | 43 | 未披露 | 192.73 | 2026-09-21 |
| Shalini Sharp | 女 | Director | 51 | 44.63万美元 | 未持股 | 2026-09-21 |
| Kurt von Emster | 男 | Director | 59 | 未披露 | 未持股 | 2026-09-21 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Michael Secora | 男 | Chief Corporate Development Officer and Chief Financial Officer | 44 | 300.73万美元 | 44.29 | 2026-09-21 |
| Neil Josephson | 男 | Chief Medical Officer | 65 | 未披露 | 未持股 | 2026-09-21 |
| Peter Olson | 男 | Chief Scientific Officer | 52 | 179.30万美元 | 9.71 | 2026-09-21 |
| Thomas Miller | 男 | Chief Executive Officer and Director | 48 | 90.62万美元 | 139.39 | 2026-09-21 |
| Frederick Manby | 男 | Chief Technology Officer and Director | 54 | 70.71万美元 | 196.44 | 2026-09-21 |
董事简历
中英对照 | 中文 | 英文- Samit Hirawat
-
Samit Hirawat 2012年至2016年-诺华公司高级副总裁兼全球项目主管。 2017年至2019年-诺华执行副总裁，肿瘤学发展负责人。 2019年至今-全球药物开发执行副总裁，首席医学官。
Samit Hirawat has served as a member of Iambic Therapeutics, Inc.'s board of directors since August 2026. He served as the Chief Medical Officer and Head of Global Drug Development at Bristol Myers Squibb Company from June 2019 to November 2025 and has since served as a consultant in the pharmaceutical industry. Dr. Hirawat has served on the board of directors of Pacira Biosciences, Inc., a pharmaceutical company, since January 2026 and currently serves on the boards of directors of several privately held companies. He holds an M.B.B.S. from the Sawai Man Singh Medical College and completed his internal medicine residency and medical oncology training at North Shore University Hospital. - Samit Hirawat 2012年至2016年-诺华公司高级副总裁兼全球项目主管。 2017年至2019年-诺华执行副总裁，肿瘤学发展负责人。 2019年至今-全球药物开发执行副总裁，首席医学官。
- Samit Hirawat has served as a member of Iambic Therapeutics, Inc.'s board of directors since August 2026. He served as the Chief Medical Officer and Head of Global Drug Development at Bristol Myers Squibb Company from June 2019 to November 2025 and has since served as a consultant in the pharmaceutical industry. Dr. Hirawat has served on the board of directors of Pacira Biosciences, Inc., a pharmaceutical company, since January 2026 and currently serves on the boards of directors of several privately held companies. He holds an M.B.B.S. from the Sawai Man Singh Medical College and completed his internal medicine residency and medical oncology training at North Shore University Hospital.
- Mary Tagliaferri
-
Mary Tagliaferri自2025年11月起担任Adarx Pharmaceuticals，Inc.董事会成员。Tagliaferri博士目前自2025年9月起担任上市生物制药公司内克塔治疗，Inc.的首席医疗官和高级副总裁，她还在2017年至2025年2月期间以相同身份任职，并自2015年1月起担任不同职务。Tagliaferri博士还自2024年8月起担任私营AI驱动的生物技术公司Iambic Therapeutics的董事会成员，并于2024年2月至2025年8月担任公共商业阶段生物制药公司Y MABS Therapeutics，Inc.的董事会成员。在此之前，Tagliaferri博士曾于2021年9月至2024年2月被百时美施贵宝收购之前在上市生物技术公司RayzeBio，Inc.的董事会任职，并于2020年11月至2024年8月在上市生物技术公司Enzo Biochem, Inc.的董事会任职。Tagliaferri博士在康奈尔大学获得农业经济和商业管理学士学位，在加州大学旧金山分校获得医学博士学位。
Mary Tagliaferri has served as a member of Adarx Pharmaceuticals, Inc.'s board of directors since November 2025. Dr. Tagliaferri currently serves as the Chief Medical Officer and Senior Vice President of Nektar Therapeutics, Inc., a public biopharmaceutical company, since September 2025, where she also served in the same capacity from 2017 to February 2025 and in various roles since January 2015. Dr. Tagliaferri also has served on the board of directors of Iambic Therapeutics, a private AI driven biotechnology company, since August 2024, and on the board of directors of Y mAbs Therapeutics, Inc., a public commercial stage biopharmaceutical company, from February 2024 to August 2025. Prior to that, Dr. Tagliaferri served on the board of directors of RayzeBio, Inc., a public biotechnology company, from September 2021 until its acquisition by Bristol Myers Squibb in February 2024, and on the board of directors of Enzo Biochem, Inc., a public biotechnology company, from November 2020 to August 2024. Dr. Tagliaferri received her B.S. in Agricultural Economics and Business Management from Cornell University and her M.D. from the University of California, San Francisco. - Mary Tagliaferri自2025年11月起担任Adarx Pharmaceuticals，Inc.董事会成员。Tagliaferri博士目前自2025年9月起担任上市生物制药公司内克塔治疗，Inc.的首席医疗官和高级副总裁，她还在2017年至2025年2月期间以相同身份任职，并自2015年1月起担任不同职务。Tagliaferri博士还自2024年8月起担任私营AI驱动的生物技术公司Iambic Therapeutics的董事会成员，并于2024年2月至2025年8月担任公共商业阶段生物制药公司Y MABS Therapeutics，Inc.的董事会成员。在此之前，Tagliaferri博士曾于2021年9月至2024年2月被百时美施贵宝收购之前在上市生物技术公司RayzeBio，Inc.的董事会任职，并于2020年11月至2024年8月在上市生物技术公司Enzo Biochem, Inc.的董事会任职。Tagliaferri博士在康奈尔大学获得农业经济和商业管理学士学位，在加州大学旧金山分校获得医学博士学位。
- Mary Tagliaferri has served as a member of Adarx Pharmaceuticals, Inc.'s board of directors since November 2025. Dr. Tagliaferri currently serves as the Chief Medical Officer and Senior Vice President of Nektar Therapeutics, Inc., a public biopharmaceutical company, since September 2025, where she also served in the same capacity from 2017 to February 2025 and in various roles since January 2015. Dr. Tagliaferri also has served on the board of directors of Iambic Therapeutics, a private AI driven biotechnology company, since August 2024, and on the board of directors of Y mAbs Therapeutics, Inc., a public commercial stage biopharmaceutical company, from February 2024 to August 2025. Prior to that, Dr. Tagliaferri served on the board of directors of RayzeBio, Inc., a public biotechnology company, from September 2021 until its acquisition by Bristol Myers Squibb in February 2024, and on the board of directors of Enzo Biochem, Inc., a public biotechnology company, from November 2020 to August 2024. Dr. Tagliaferri received her B.S. in Agricultural Economics and Business Management from Cornell University and her M.D. from the University of California, San Francisco.
- William Rastetter
-
William Rastetter自2023年3月起担任Iambic Therapeutics，Inc.董事会成员。2014年1月起担任Dar é Bioscience，Inc.董事，2011年12月起担任Fate Therapeutics,2010年2月起担任神经分泌生物科学。他分别自2019年7月、2011年12月和2011年5月起担任这些委员会的主席。Rastetter博士此前曾于2013年4月起担任Grail, Inc.的临时首席执行官兼董事长，并担任Regulus Therapeutics公司的董事会成员，直至其于2025年6月被诺华公司收购。从2006年到2013年初，Rastetter博士是风险投资公司Venrock的合伙人。他于1986年12月至2003年11月担任IDEC Pharmaceuticals的首席执行官，并于2003年11月至2005年担任渤健 Idec，Inc.的执行主席。Rastetter博士拥有麻省理工学院的化学硕士学位和哈佛大学的化学硕士和博士学位。
William Rastetter has served as a member of Iambic Therapeutics, Inc.'s board of directors since March 2023. He has served as a director of Daré Bioscience, Inc. since January 2014, Fate Therapeutics, Inc. since December 2011, and Neurocrine Biosciences, Inc. since February 2010. He has served as chair of those boards since July 2019, December 2011, and May 2011, respectively. Dr. Rastetter previously served as the Interim Chief Executive Officer and Chairman of Grail, Inc., and as a member of the board of directors of Regulus Therapeutics, Inc. from April 2013 until its acquisition by Novartis AG in June 2025. Dr. Rastetter was a partner in the venture capital firm, Venrock, from 2006 through early 2013. He was Chief Executive Officer of IDEC Pharmaceuticals from December 1986 through November 2003, and was Executive Chairman of Biogen Idec, Inc. from November 2003 through 2005. Dr. Rastetter holds an S.B. in Chemistry from the Massachusetts Institute of Technology and an M.A. and Ph.D. in Chemistry from Harvard University. - William Rastetter自2023年3月起担任Iambic Therapeutics，Inc.董事会成员。2014年1月起担任Dar é Bioscience，Inc.董事，2011年12月起担任Fate Therapeutics,2010年2月起担任神经分泌生物科学。他分别自2019年7月、2011年12月和2011年5月起担任这些委员会的主席。Rastetter博士此前曾于2013年4月起担任Grail, Inc.的临时首席执行官兼董事长，并担任Regulus Therapeutics公司的董事会成员，直至其于2025年6月被诺华公司收购。从2006年到2013年初，Rastetter博士是风险投资公司Venrock的合伙人。他于1986年12月至2003年11月担任IDEC Pharmaceuticals的首席执行官，并于2003年11月至2005年担任渤健 Idec，Inc.的执行主席。Rastetter博士拥有麻省理工学院的化学硕士学位和哈佛大学的化学硕士和博士学位。
- William Rastetter has served as a member of Iambic Therapeutics, Inc.'s board of directors since March 2023. He has served as a director of Daré Bioscience, Inc. since January 2014, Fate Therapeutics, Inc. since December 2011, and Neurocrine Biosciences, Inc. since February 2010. He has served as chair of those boards since July 2019, December 2011, and May 2011, respectively. Dr. Rastetter previously served as the Interim Chief Executive Officer and Chairman of Grail, Inc., and as a member of the board of directors of Regulus Therapeutics, Inc. from April 2013 until its acquisition by Novartis AG in June 2025. Dr. Rastetter was a partner in the venture capital firm, Venrock, from 2006 through early 2013. He was Chief Executive Officer of IDEC Pharmaceuticals from December 1986 through November 2003, and was Executive Chairman of Biogen Idec, Inc. from November 2003 through 2005. Dr. Rastetter holds an S.B. in Chemistry from the Massachusetts Institute of Technology and an M.A. and Ph.D. in Chemistry from Harvard University.
- Thomas Miller
-
Thomas Miller自2019年10月共同创立公司以来，一直担任Iambic Therapeutics，Inc.的董事会成员，并自2020年4月起担任Iambic Therapeutics，Inc.的首席执行官。此前，米勒博士曾于2013年2月至2022年3月担任化学教授，并于2008年6月至2013年2月担任加州理工学院化学助理教授。他目前担任基因组诊断公司Veracyte, Inc.的董事。Miller博士拥有得克萨斯农工大学化学和数学学士学位、伦敦大学学院理论化学硕士学位和牛津大学理论化学博士学位。
Thomas Miller has served as a member of Iambic Therapeutics, Inc.'s board of directors since he co founded the Company in October 2019 and as Iambic Therapeutics, Inc.'s Chief Executive Officer since April 2020. Previously, Dr. Miller was a Professor of chemistry from February 2013 to March 2022 and Assistant Professor of Chemistry from June 2008 to February 2013 at the California Institute of Technology. He currently serves as a director of Veracyte, Inc., a genomic diagnostics company. Dr. Miller holds a B.S. in Chemistry and Mathematics from Texas A&M University, an M.Phil. in Theoretical Chemistry from University College London and a Ph.D. in Theoretical Chemistry from the University of Oxford. - Thomas Miller自2019年10月共同创立公司以来，一直担任Iambic Therapeutics，Inc.的董事会成员，并自2020年4月起担任Iambic Therapeutics，Inc.的首席执行官。此前，米勒博士曾于2013年2月至2022年3月担任化学教授，并于2008年6月至2013年2月担任加州理工学院化学助理教授。他目前担任基因组诊断公司Veracyte, Inc.的董事。Miller博士拥有得克萨斯农工大学化学和数学学士学位、伦敦大学学院理论化学硕士学位和牛津大学理论化学博士学位。
- Thomas Miller has served as a member of Iambic Therapeutics, Inc.'s board of directors since he co founded the Company in October 2019 and as Iambic Therapeutics, Inc.'s Chief Executive Officer since April 2020. Previously, Dr. Miller was a Professor of chemistry from February 2013 to March 2022 and Assistant Professor of Chemistry from June 2008 to February 2013 at the California Institute of Technology. He currently serves as a director of Veracyte, Inc., a genomic diagnostics company. Dr. Miller holds a B.S. in Chemistry and Mathematics from Texas A&M University, an M.Phil. in Theoretical Chemistry from University College London and a Ph.D. in Theoretical Chemistry from the University of Oxford.
- R. Jacob Vogelstein
-
R. Jacob Vogelstein自2021年7月起担任Iambic Therapeutics，Inc.董事会成员。自2020年6月起，他担任他共同创立的投资公司Catalio Capital Management，LP的管理合伙人，该公司专注于生物医学技术和生命科学领域。2016年1月至2020年12月，他在Camden Partners Holdings，LLC担任普通合伙人，这是一家从T. Rowe Price分拆出来的私募股权公司。Vogelstein博士目前在几家私营公司的董事会任职。他拥有布朗大学生物电气工程学士学位和约翰霍普金斯大学医学院生物医学工程博士学位。
R. Jacob Vogelstein has served as a member of Iambic Therapeutics, Inc.'s board of directors since July 2021. He has served as a Managing Partner of Catalio Capital Management, LP, an investment firm he co founded, specializing in the biomedical technology and life sciences sectors, since June 2020. From January 2016 to December 2020, he served as a General Partner at Camden Partners Holdings, LLC, a private equity firm that spun out of T. Rowe Price. Dr. Vogelstein currently serves on the boards of directors of several privately held companies. He holds a B.S. in Bio Electrical Engineering from Brown University and a Ph.D. in Biomedical Engineering from the Johns Hopkins University School of Medicine. - R. Jacob Vogelstein自2021年7月起担任Iambic Therapeutics，Inc.董事会成员。自2020年6月起，他担任他共同创立的投资公司Catalio Capital Management，LP的管理合伙人，该公司专注于生物医学技术和生命科学领域。2016年1月至2020年12月，他在Camden Partners Holdings，LLC担任普通合伙人，这是一家从T. Rowe Price分拆出来的私募股权公司。Vogelstein博士目前在几家私营公司的董事会任职。他拥有布朗大学生物电气工程学士学位和约翰霍普金斯大学医学院生物医学工程博士学位。
- R. Jacob Vogelstein has served as a member of Iambic Therapeutics, Inc.'s board of directors since July 2021. He has served as a Managing Partner of Catalio Capital Management, LP, an investment firm he co founded, specializing in the biomedical technology and life sciences sectors, since June 2020. From January 2016 to December 2020, he served as a General Partner at Camden Partners Holdings, LLC, a private equity firm that spun out of T. Rowe Price. Dr. Vogelstein currently serves on the boards of directors of several privately held companies. He holds a B.S. in Bio Electrical Engineering from Brown University and a Ph.D. in Biomedical Engineering from the Johns Hopkins University School of Medicine.
- Frederick Manby
-
Frederick Manby自2019年10月共同创立公司以来一直担任Iambic Therapeutics，Inc.的董事会成员，并自2020年4月起担任Iambic Therapeutics，Inc.的首席技术官。此前，Manby博士曾于2010年8月至2022年3月在布里斯托大学担任理论化学教授。他拥有约克大学化学学士和博士学位。
Frederick Manby has served as a member of Iambic Therapeutics, Inc.'s board of directors since he co founded the Company in October 2019 and as Iambic Therapeutics, Inc.'s Chief Technology Officer since April 2020. Previously, Dr. Manby was a Professor of Theoretical Chemistry from August 2010 to March 2022 at the University of Bristol. He holds a B.Sc. and Ph.D. in Chemistry from the University of York. - Frederick Manby自2019年10月共同创立公司以来一直担任Iambic Therapeutics，Inc.的董事会成员，并自2020年4月起担任Iambic Therapeutics，Inc.的首席技术官。此前，Manby博士曾于2010年8月至2022年3月在布里斯托大学担任理论化学教授。他拥有约克大学化学学士和博士学位。
- Frederick Manby has served as a member of Iambic Therapeutics, Inc.'s board of directors since he co founded the Company in October 2019 and as Iambic Therapeutics, Inc.'s Chief Technology Officer since April 2020. Previously, Dr. Manby was a Professor of Theoretical Chemistry from August 2010 to March 2022 at the University of Bristol. He holds a B.Sc. and Ph.D. in Chemistry from the University of York.
- Shalini Sharp
-
Shalini Sharp自2025年9月起担任Iambic Therapeutics，Inc.董事会成员。自2026年1月起，她在加州大学伯克利分校担任商业和政策专业教员。她于2012年5月至2020年10月在生物制药公司Ultragenyx药业公司担任执行副总裁兼首席财务官。Sharp女士目前担任BeOne Medicines Ltd.（前身为百济神州有限公司）的董事会成员，自2024年9月起担任；自2020年2月起担任神经分泌生物科学 Biosciences，Inc.；自2021年5月起担任欧加隆 & Co.；自2024年1月起担任Septerna，Inc.。她此前曾在Mirati Therapeutics, Inc.的董事会任职，此前于2021年3月至2024年1月被BMS收购，于2018年11月至2023年4月在Sutro Biopharma，于2018年12月至2022年6月在Precision生物科学，Inc.任职。她拥有哈佛大学英美文学学士学位和哈佛商学院工商管理硕士学位。
Shalini Sharp has served as a member of Iambic Therapeutics, Inc.'s board of directors since September 2025. Since January 2026, she has served as a professional faculty member in business and policy at the University of California, Berkeley. She served as Executive Vice President and Chief Financial Officer of Ultragenyx Pharmaceutical, Inc., a biopharmaceutical company, from May 2012 until October 2020. Ms. Sharp currently serves on the boards of directors of BeOne Medicines Ltd., formerly BeiGene, Ltd., since September 2024, Neurocrine Biosciences, Inc. since February 2020, Organon & Co. since May 2021 and Septerna, Inc. since January 2024. She previously served on the boards of directors of Mirati Therapeutics, Inc., prior to its acquisition by BMS from March 2021 to January 2024, Sutro Biopharma, Inc. from November 2018 to April 2023, and Precision BioSciences, Inc. from December 2018 to June 2022. She holds an A.B. in English and American Literature from Harvard University and an M.B.A. from Harvard Business School. - Shalini Sharp自2025年9月起担任Iambic Therapeutics，Inc.董事会成员。自2026年1月起，她在加州大学伯克利分校担任商业和政策专业教员。她于2012年5月至2020年10月在生物制药公司Ultragenyx药业公司担任执行副总裁兼首席财务官。Sharp女士目前担任BeOne Medicines Ltd.（前身为百济神州有限公司）的董事会成员，自2024年9月起担任；自2020年2月起担任神经分泌生物科学 Biosciences，Inc.；自2021年5月起担任欧加隆 & Co.；自2024年1月起担任Septerna，Inc.。她此前曾在Mirati Therapeutics, Inc.的董事会任职，此前于2021年3月至2024年1月被BMS收购，于2018年11月至2023年4月在Sutro Biopharma，于2018年12月至2022年6月在Precision生物科学，Inc.任职。她拥有哈佛大学英美文学学士学位和哈佛商学院工商管理硕士学位。
- Shalini Sharp has served as a member of Iambic Therapeutics, Inc.'s board of directors since September 2025. Since January 2026, she has served as a professional faculty member in business and policy at the University of California, Berkeley. She served as Executive Vice President and Chief Financial Officer of Ultragenyx Pharmaceutical, Inc., a biopharmaceutical company, from May 2012 until October 2020. Ms. Sharp currently serves on the boards of directors of BeOne Medicines Ltd., formerly BeiGene, Ltd., since September 2024, Neurocrine Biosciences, Inc. since February 2020, Organon & Co. since May 2021 and Septerna, Inc. since January 2024. She previously served on the boards of directors of Mirati Therapeutics, Inc., prior to its acquisition by BMS from March 2021 to January 2024, Sutro Biopharma, Inc. from November 2018 to April 2023, and Precision BioSciences, Inc. from December 2018 to June 2022. She holds an A.B. in English and American Literature from Harvard University and an M.B.A. from Harvard Business School.
- Samit Hirawat
-
Samit Hirawat自2026年8月起担任Iambic Therapeutics，Inc.董事会成员。他曾于2019年6月至2025年11月在百时美施贵宝公司担任首席医疗官和全球药物开发主管，此后担任制药行业顾问。Hirawat博士自2026年1月起担任制药公司Pacira BioSciences, Inc.的董事会成员，目前在多家私营公司的董事会任职。他拥有Sawai Man Singh医学院的工商管理硕士学位，并在北岸大学医院完成了内科住院医师和医学肿瘤学培训。
Samit Hirawat has served as a member of Iambic Therapeutics, Inc.'s board of directors since August 2026. He served as the Chief Medical Officer and Head of Global Drug Development at Bristol Myers Squibb Company from June 2019 to November 2025 and has since served as a consultant in the pharmaceutical industry. Dr. Hirawat has served on the board of directors of Pacira Biosciences, Inc., a pharmaceutical company, since January 2026 and currently serves on the boards of directors of several privately held companies. He holds an M.B.B.S. from the Sawai Man Singh Medical College and completed his internal medicine residency and medical oncology training at North Shore University Hospital. - Samit Hirawat自2026年8月起担任Iambic Therapeutics，Inc.董事会成员。他曾于2019年6月至2025年11月在百时美施贵宝公司担任首席医疗官和全球药物开发主管，此后担任制药行业顾问。Hirawat博士自2026年1月起担任制药公司Pacira BioSciences, Inc.的董事会成员，目前在多家私营公司的董事会任职。他拥有Sawai Man Singh医学院的工商管理硕士学位，并在北岸大学医院完成了内科住院医师和医学肿瘤学培训。
- Samit Hirawat has served as a member of Iambic Therapeutics, Inc.'s board of directors since August 2026. He served as the Chief Medical Officer and Head of Global Drug Development at Bristol Myers Squibb Company from June 2019 to November 2025 and has since served as a consultant in the pharmaceutical industry. Dr. Hirawat has served on the board of directors of Pacira Biosciences, Inc., a pharmaceutical company, since January 2026 and currently serves on the boards of directors of several privately held companies. He holds an M.B.B.S. from the Sawai Man Singh Medical College and completed his internal medicine residency and medical oncology training at North Shore University Hospital.
- Evan Rachlin
-
埃文·拉奇林自2023年9月起担任Iambic Therapeutics，Inc.董事会成员。自2023年1月以来，他一直在他共同创立的风险投资公司Ascenta Capital担任管理合伙人。2019年4月至2022年4月，Rachlin博士在私人投资平台Blackstone Life Sciences担任董事总经理。2015年6月至2019年3月，他在制药和生物技术公司Moderna, Inc.担任战略主管。他于2012年9月至2015年5月担任贝恩资本风险投资公司的负责人，并在麦肯锡公司开始了他的职业生涯。他拥有哈佛学院生物化学和日语学士学位，以及哈佛医学院和哈佛商学院的医学博士和工商管理硕士学位。
Evan Rachlin has served as a member of Iambic Therapeutics, Inc.'s board of directors since September 2023. He has served as a Managing Partner at Ascenta Capital, a venture capital firm he co founded, since January 2023. From April 2019 to April 2022, Dr. Rachlin served as a Managing Director at Blackstone Life Sciences, a private investment platform. From June 2015 to March 2019, he served as Head of Strategy at Moderna, Inc., a pharmaceutical and biotechnology company. He was a Principal at Bain Capital Ventures from September 2012 to May 2015, and began his career at McKinsey & Company. He holds an A.B. in Biochemistry and Japanese from Harvard College and an M.D. and M.B.A. from Harvard Medical School and Harvard Business School. - 埃文·拉奇林自2023年9月起担任Iambic Therapeutics，Inc.董事会成员。自2023年1月以来，他一直在他共同创立的风险投资公司Ascenta Capital担任管理合伙人。2019年4月至2022年4月，Rachlin博士在私人投资平台Blackstone Life Sciences担任董事总经理。2015年6月至2019年3月，他在制药和生物技术公司Moderna, Inc.担任战略主管。他于2012年9月至2015年5月担任贝恩资本风险投资公司的负责人，并在麦肯锡公司开始了他的职业生涯。他拥有哈佛学院生物化学和日语学士学位，以及哈佛医学院和哈佛商学院的医学博士和工商管理硕士学位。
- Evan Rachlin has served as a member of Iambic Therapeutics, Inc.'s board of directors since September 2023. He has served as a Managing Partner at Ascenta Capital, a venture capital firm he co founded, since January 2023. From April 2019 to April 2022, Dr. Rachlin served as a Managing Director at Blackstone Life Sciences, a private investment platform. From June 2015 to March 2019, he served as Head of Strategy at Moderna, Inc., a pharmaceutical and biotechnology company. He was a Principal at Bain Capital Ventures from September 2012 to May 2015, and began his career at McKinsey & Company. He holds an A.B. in Biochemistry and Japanese from Harvard College and an M.D. and M.B.A. from Harvard Medical School and Harvard Business School.
- Shalini Sharp
-
Shalini Sharp女士，拥有哈佛大学英语和美国文学和语言学士学位、哈佛商学院工商管理硕士学位。职业生涯早期就职于Elan Pharmaceuticals、McKinsey&Company和高盛集团（Goldman Sachs）。1995年-2012年5月，在临床阶段免疫肿瘤学上市公司Agenus,Inc.（纳斯达克股票代码：AGEN）任职，2003年8月起担任多项职务，包括首席财务官，2012年5月-2018年6月期间任百济神州有限公司董事会成员；2012年5月-2020年10月，担任生物制药上市公司Ultragenyx Pharmaceuticals Inc.（纳斯达克股票代码：RARE）执行副总裁兼首席财务官；2017年4月-2019年6月，担任Array Biopharma董事会成员（于2019年6月被收购）；2018年11月-2023年11月，担任生物制药上市公司Sutro Biopharma,Inc.（纳斯达克股票代码：STRO）董事会成员；2018年12月-2022年6月，担任基因编辑上市公司Precision BioSciences,Inc.（纳斯达克股票代码：DTIL）董事会成员；2020年6月-2021年2月，担任特殊目的收购公司Panacea Acquisition Corp.（纳斯达克股票代码：PANA）董事会成员（直至2021年2月完成业务合并，原内容“2020年7月起”等表述依补充信息调整）；2021年3月-2024年1月，担任Mirati Therapeutics,Inc.董事会成员（于2024年1月被收购）；2024年1月起，担任Septerna，Inc.董事会成员；目前担任生物制药上市公司Neurocrine Biosciences,Inc.（纳斯达克股票代码：NBIX）、医疗保健上市公司Organon&Co（纳斯达克股票代码：OGN）和百济神州有限公司（纳斯达克股票代码：BGNE）等的董事会成员，2024年9月27日加入百济神州有限公司董事会，自2024年9月起任百济神州有限公司独立非执行董事，于年度股东大会日期前一直担任第三类董事。
Shalini Sharp has served as a member of Iambic Therapeutics, Inc.'s board of directors since September 2025. Since January 2026, she has served as a professional faculty member in business and policy at the University of California, Berkeley. She served as Executive Vice President and Chief Financial Officer of Ultragenyx Pharmaceutical, Inc., a biopharmaceutical company, from May 2012 until October 2020. Ms. Sharp currently serves on the boards of directors of BeOne Medicines Ltd., formerly BeiGene, Ltd., since September 2024, Neurocrine Biosciences, Inc. since February 2020, Organon & Co. since May 2021 and Septerna, Inc. since January 2024. She previously served on the boards of directors of Mirati Therapeutics, Inc., prior to its acquisition by BMS from March 2021 to January 2024, Sutro Biopharma, Inc. from November 2018 to April 2023, and Precision BioSciences, Inc. from December 2018 to June 2022. She holds an A.B. in English and American Literature from Harvard University and an M.B.A. from Harvard Business School. - Shalini Sharp女士，拥有哈佛大学英语和美国文学和语言学士学位、哈佛商学院工商管理硕士学位。职业生涯早期就职于Elan Pharmaceuticals、McKinsey&Company和高盛集团（Goldman Sachs）。1995年-2012年5月，在临床阶段免疫肿瘤学上市公司Agenus,Inc.（纳斯达克股票代码：AGEN）任职，2003年8月起担任多项职务，包括首席财务官，2012年5月-2018年6月期间任百济神州有限公司董事会成员；2012年5月-2020年10月，担任生物制药上市公司Ultragenyx Pharmaceuticals Inc.（纳斯达克股票代码：RARE）执行副总裁兼首席财务官；2017年4月-2019年6月，担任Array Biopharma董事会成员（于2019年6月被收购）；2018年11月-2023年11月，担任生物制药上市公司Sutro Biopharma,Inc.（纳斯达克股票代码：STRO）董事会成员；2018年12月-2022年6月，担任基因编辑上市公司Precision BioSciences,Inc.（纳斯达克股票代码：DTIL）董事会成员；2020年6月-2021年2月，担任特殊目的收购公司Panacea Acquisition Corp.（纳斯达克股票代码：PANA）董事会成员（直至2021年2月完成业务合并，原内容“2020年7月起”等表述依补充信息调整）；2021年3月-2024年1月，担任Mirati Therapeutics,Inc.董事会成员（于2024年1月被收购）；2024年1月起，担任Septerna，Inc.董事会成员；目前担任生物制药上市公司Neurocrine Biosciences,Inc.（纳斯达克股票代码：NBIX）、医疗保健上市公司Organon&Co（纳斯达克股票代码：OGN）和百济神州有限公司（纳斯达克股票代码：BGNE）等的董事会成员，2024年9月27日加入百济神州有限公司董事会，自2024年9月起任百济神州有限公司独立非执行董事，于年度股东大会日期前一直担任第三类董事。
- Shalini Sharp has served as a member of Iambic Therapeutics, Inc.'s board of directors since September 2025. Since January 2026, she has served as a professional faculty member in business and policy at the University of California, Berkeley. She served as Executive Vice President and Chief Financial Officer of Ultragenyx Pharmaceutical, Inc., a biopharmaceutical company, from May 2012 until October 2020. Ms. Sharp currently serves on the boards of directors of BeOne Medicines Ltd., formerly BeiGene, Ltd., since September 2024, Neurocrine Biosciences, Inc. since February 2020, Organon & Co. since May 2021 and Septerna, Inc. since January 2024. She previously served on the boards of directors of Mirati Therapeutics, Inc., prior to its acquisition by BMS from March 2021 to January 2024, Sutro Biopharma, Inc. from November 2018 to April 2023, and Precision BioSciences, Inc. from December 2018 to June 2022. She holds an A.B. in English and American Literature from Harvard University and an M.B.A. from Harvard Business School.
- Kurt von Emster
-
Kurt von Emster，目前担任风险投资公司Abingworth LLP的管理合伙人，自2015年1月起担任该公司的合伙人。von Emster先生自2020年12月起担任生物技术公司Tizona Therapeutics，Inc.的董事会成员，自2020年12月起担任免疫治疗公司Trishula Therapeutics，Inc.，自2020年12月起担任制药公司Orbus Therapeutics，Inc.，自2020年7月起担任专业制药公司SFJ Pharmaceuticals，Inc.，自2020年4月起担任生物技术公司Jasper Therapeutics, Inc.，自2019年11月起担任生物制药疫苗公司VaxcyteVaxcyte，自2015年7月起担任生物技术公司CymaBay Therapeutics，Inc.，自2009年4月起担任。von Emster先生此前曾在以下公司的董事会任职：CRISPR Therapeutics，Inc.于2015年3月至2019年6月Kesios Therapeutics Ltd.于2015年11月至2017年1月Cytos Biotechnology AG于2012年11月至2016年1月（于2016年1月合并并更名为Kuros Biosciences AG），Somaxon制药 Inc.于2014年2月至2015年3月Facet Biotechnology Corporation（于2010年4月被雅培收购）于2009年2月至2010年4月以及TERM3（于2013年3月被Pernix疗法控股，Inc.收购）于2005年8月至2013年3月。此外，von Emster先生于2009年与他人共同创立了专注于医疗保健的投资公司venBio LLC，并担任合伙人至2014年。在此之前，von Emster先生于2000年至2009年担任生物技术私募股权公司MPM Capital，Inc.的普通合伙人。von Emster先生还曾于1989年至2000年在富兰克林邓普顿集团担任生物技术和医疗保健分析师和投资组合经理。von Emster先生在加州大学圣巴巴拉分校获得商业和经济学学士学位，是一名特许金融分析师（C.F.A。）。
Kurt von Emster has served as a member of Iambic Therapeutics, Inc.'s board of directors since September 2023. He joined Abingworth LLP, a venture capital firm, as a Partner in January 2015 and has served as a Managing Partner since July 2015. Abingworth LLP was acquired by The Carlyle Group in 2022 and is a wholly owned subsidiary of The Carlyle Group. From May 2009 until January 2015, he served as a Partner at venBio LLC, a venture capital firm he co founded. He currently serves on the boards of directors of Jasper Therapeutics, Inc., a biotechnology company, and several privately held companies. He previously served on the boards of directors of CymaBay Therapeutics, Inc. until April 2024, CRISPR Therapeutics AG until June 2019, Vaxcyte, Inc. until June 2022, and Vera Therapeutics, Inc. until May 2022. Mr. von Emster holds a B.S. in Business and Economics from the University of California, Santa Barbara and is a Chartered Financial Analyst (CFA). - Kurt von Emster，目前担任风险投资公司Abingworth LLP的管理合伙人，自2015年1月起担任该公司的合伙人。von Emster先生自2020年12月起担任生物技术公司Tizona Therapeutics，Inc.的董事会成员，自2020年12月起担任免疫治疗公司Trishula Therapeutics，Inc.，自2020年12月起担任制药公司Orbus Therapeutics，Inc.，自2020年7月起担任专业制药公司SFJ Pharmaceuticals，Inc.，自2020年4月起担任生物技术公司Jasper Therapeutics, Inc.，自2019年11月起担任生物制药疫苗公司VaxcyteVaxcyte，自2015年7月起担任生物技术公司CymaBay Therapeutics，Inc.，自2009年4月起担任。von Emster先生此前曾在以下公司的董事会任职：CRISPR Therapeutics，Inc.于2015年3月至2019年6月Kesios Therapeutics Ltd.于2015年11月至2017年1月Cytos Biotechnology AG于2012年11月至2016年1月（于2016年1月合并并更名为Kuros Biosciences AG），Somaxon制药 Inc.于2014年2月至2015年3月Facet Biotechnology Corporation（于2010年4月被雅培收购）于2009年2月至2010年4月以及TERM3（于2013年3月被Pernix疗法控股，Inc.收购）于2005年8月至2013年3月。此外，von Emster先生于2009年与他人共同创立了专注于医疗保健的投资公司venBio LLC，并担任合伙人至2014年。在此之前，von Emster先生于2000年至2009年担任生物技术私募股权公司MPM Capital，Inc.的普通合伙人。von Emster先生还曾于1989年至2000年在富兰克林邓普顿集团担任生物技术和医疗保健分析师和投资组合经理。von Emster先生在加州大学圣巴巴拉分校获得商业和经济学学士学位，是一名特许金融分析师（C.F.A。）。
- Kurt von Emster has served as a member of Iambic Therapeutics, Inc.'s board of directors since September 2023. He joined Abingworth LLP, a venture capital firm, as a Partner in January 2015 and has served as a Managing Partner since July 2015. Abingworth LLP was acquired by The Carlyle Group in 2022 and is a wholly owned subsidiary of The Carlyle Group. From May 2009 until January 2015, he served as a Partner at venBio LLC, a venture capital firm he co founded. He currently serves on the boards of directors of Jasper Therapeutics, Inc., a biotechnology company, and several privately held companies. He previously served on the boards of directors of CymaBay Therapeutics, Inc. until April 2024, CRISPR Therapeutics AG until June 2019, Vaxcyte, Inc. until June 2022, and Vera Therapeutics, Inc. until May 2022. Mr. von Emster holds a B.S. in Business and Economics from the University of California, Santa Barbara and is a Chartered Financial Analyst (CFA).
高管简历
中英对照 | 中文 | 英文- Michael Secora
Michael Secora自2025年1月起担任Iambic Therapeutics，Inc.的首席财务官和首席企业发展官。在加入Iambic Therapeutics，Inc.之前，他曾于2020年3月至2024年11月在TechBio的临床阶段公司Recursion Pharmaceuticals, Inc.担任首席财务官，并于2024年11月至2024年12月担任顾问。从2010年7月到2020年2月，Secora博士在投资公司Laurion Capital Management LP担任董事总经理兼资本市场和风险投资主管。他拥有麻省理工学院数学和物理学士学位以及普林斯顿大学应用和计算数学博士学位。
Michael Secora has served as Iambic Therapeutics, Inc.'s Chief Financial Officer and Chief Corporate Development Officer since January 2025. Prior to joining Iambic Therapeutics, Inc., he served as Chief Financial Officer at Recursion Pharmaceuticals, Inc., a clinical stage TechBio company, from March 2020 through November 2024 and as Advisor from November 2024 through December 2024. From July 2010 through February 2020, Dr. Secora served as Managing Director and Head of Capital Markets and Venture at Laurion Capital Management LP, an investment firm. He holds B.S. degrees in Mathematics and Physics from the Massachusetts Institute of Technology and a Ph.D. in Applied and Computational Mathematics from Princeton University.- Michael Secora自2025年1月起担任Iambic Therapeutics，Inc.的首席财务官和首席企业发展官。在加入Iambic Therapeutics，Inc.之前，他曾于2020年3月至2024年11月在TechBio的临床阶段公司Recursion Pharmaceuticals, Inc.担任首席财务官，并于2024年11月至2024年12月担任顾问。从2010年7月到2020年2月，Secora博士在投资公司Laurion Capital Management LP担任董事总经理兼资本市场和风险投资主管。他拥有麻省理工学院数学和物理学士学位以及普林斯顿大学应用和计算数学博士学位。
- Michael Secora has served as Iambic Therapeutics, Inc.'s Chief Financial Officer and Chief Corporate Development Officer since January 2025. Prior to joining Iambic Therapeutics, Inc., he served as Chief Financial Officer at Recursion Pharmaceuticals, Inc., a clinical stage TechBio company, from March 2020 through November 2024 and as Advisor from November 2024 through December 2024. From July 2010 through February 2020, Dr. Secora served as Managing Director and Head of Capital Markets and Venture at Laurion Capital Management LP, an investment firm. He holds B.S. degrees in Mathematics and Physics from the Massachusetts Institute of Technology and a Ph.D. in Applied and Computational Mathematics from Princeton University.
- Neil Josephson
Neil Josephson自2024年1月起担任Iambic Therapeutics，Inc.的首席医疗官。2019年4月至2023年1月，他在生物技术公司Zymeworks公司担任多个临床开发领导职务，包括2021年11月至2023年1月担任首席医疗官，2021年5月至2021年11月担任临时首席医疗官，2020年8月至2021年11月担任临床研究高级副总裁。在加入Zymeworks之前，Josephson博士曾于2013年10月至2019年4月在生物技术公司Seattle Genetics, Inc.担任临床开发方面日益负责的职位，最近担任的是临床开发副总裁。Josephson博士在华盛顿大学完成了血液学和肿瘤学的研究金培训，并拥有达特茅斯学院的生物学学士学位和哥伦比亚大学的医学博士学位。
Neil Josephson has served as Iambic Therapeutics, Inc.'s Chief Medical Officer since January 2024. From April 2019 to January 2023, he served in various clinical development leadership roles at Zymeworks, Inc., a biotechnology company, including as Chief Medical Officer from November 2021 to January 2023, as Interim Chief Medical Officer from May 2021 to November 2021, and as Senior Vice President, Clinical Research from August 2020 to November 2021. Prior to Zymeworks, Dr. Josephson served in positions of increasing responsibility in clinical development at Seattle Genetics, Inc., a biotechnology company, from October 2013 to April 2019, most recently as Vice President, Clinical Development. Dr. Josephson completed fellowship training in Hematology and Oncology at the University of Washington and holds a B.A. in Biology from Dartmouth College and an M.D. from Columbia University.- Neil Josephson自2024年1月起担任Iambic Therapeutics，Inc.的首席医疗官。2019年4月至2023年1月，他在生物技术公司Zymeworks公司担任多个临床开发领导职务，包括2021年11月至2023年1月担任首席医疗官，2021年5月至2021年11月担任临时首席医疗官，2020年8月至2021年11月担任临床研究高级副总裁。在加入Zymeworks之前，Josephson博士曾于2013年10月至2019年4月在生物技术公司Seattle Genetics, Inc.担任临床开发方面日益负责的职位，最近担任的是临床开发副总裁。Josephson博士在华盛顿大学完成了血液学和肿瘤学的研究金培训，并拥有达特茅斯学院的生物学学士学位和哥伦比亚大学的医学博士学位。
- Neil Josephson has served as Iambic Therapeutics, Inc.'s Chief Medical Officer since January 2024. From April 2019 to January 2023, he served in various clinical development leadership roles at Zymeworks, Inc., a biotechnology company, including as Chief Medical Officer from November 2021 to January 2023, as Interim Chief Medical Officer from May 2021 to November 2021, and as Senior Vice President, Clinical Research from August 2020 to November 2021. Prior to Zymeworks, Dr. Josephson served in positions of increasing responsibility in clinical development at Seattle Genetics, Inc., a biotechnology company, from October 2013 to April 2019, most recently as Vice President, Clinical Development. Dr. Josephson completed fellowship training in Hematology and Oncology at the University of Washington and holds a B.A. in Biology from Dartmouth College and an M.D. from Columbia University.
- Peter Olson
彼得·奥尔森自2024年12月起担任Iambic Therapeutics，Inc.的首席科学官。2024年1月至2024年12月，他在生物制药公司百时美施贵宝公司（BMS）担任研究副总裁。2015年10月至2024年1月，Olson博士在BMS于2024年1月收购的肿瘤学公司Mirati Therapeutics, Inc.担任多个执行职务，最近一次是在2024年1月担任研究部副总裁，2022年1月至2024年1月担任研究部执行董事，2019年5月至2022年1月担任研究部高级总监。他拥有加州大学戴维斯分校的生物化学学士学位和加州大学圣地亚哥分校的生物学博士学位。
Peter Olson has served as Iambic Therapeutics, Inc.'s Chief Scientific Officer since December 2024. From January 2024 to December 2024, he served as Vice President, Research at Bristol Myers Squibb Company (BMS), a biopharmaceutical company. From October 2015 to January 2024, Dr. Olson served in various executive roles at Mirati Therapeutics, Inc., an oncology company acquired by BMS in January 2024, most recently as Vice President, Research in January 2024, Executive Director of Research from January 2022 to January 2024 and Senior Director of Research from May 2019 to January 2022. He holds a B.S. in Biochemistry from the University of California, Davis and a Ph.D. in Biology from the University of California, San Diego.- 彼得·奥尔森自2024年12月起担任Iambic Therapeutics，Inc.的首席科学官。2024年1月至2024年12月，他在生物制药公司百时美施贵宝公司（BMS）担任研究副总裁。2015年10月至2024年1月，Olson博士在BMS于2024年1月收购的肿瘤学公司Mirati Therapeutics, Inc.担任多个执行职务，最近一次是在2024年1月担任研究部副总裁，2022年1月至2024年1月担任研究部执行董事，2019年5月至2022年1月担任研究部高级总监。他拥有加州大学戴维斯分校的生物化学学士学位和加州大学圣地亚哥分校的生物学博士学位。
- Peter Olson has served as Iambic Therapeutics, Inc.'s Chief Scientific Officer since December 2024. From January 2024 to December 2024, he served as Vice President, Research at Bristol Myers Squibb Company (BMS), a biopharmaceutical company. From October 2015 to January 2024, Dr. Olson served in various executive roles at Mirati Therapeutics, Inc., an oncology company acquired by BMS in January 2024, most recently as Vice President, Research in January 2024, Executive Director of Research from January 2022 to January 2024 and Senior Director of Research from May 2019 to January 2022. He holds a B.S. in Biochemistry from the University of California, Davis and a Ph.D. in Biology from the University of California, San Diego.
- Thomas Miller
Thomas Miller自2019年10月共同创立公司以来，一直担任Iambic Therapeutics，Inc.的董事会成员，并自2020年4月起担任Iambic Therapeutics，Inc.的首席执行官。此前，米勒博士曾于2013年2月至2022年3月担任化学教授，并于2008年6月至2013年2月担任加州理工学院化学助理教授。他目前担任基因组诊断公司Veracyte, Inc.的董事。Miller博士拥有得克萨斯农工大学化学和数学学士学位、伦敦大学学院理论化学硕士学位和牛津大学理论化学博士学位。
Thomas Miller has served as a member of Iambic Therapeutics, Inc.'s board of directors since he co founded the Company in October 2019 and as Iambic Therapeutics, Inc.'s Chief Executive Officer since April 2020. Previously, Dr. Miller was a Professor of chemistry from February 2013 to March 2022 and Assistant Professor of Chemistry from June 2008 to February 2013 at the California Institute of Technology. He currently serves as a director of Veracyte, Inc., a genomic diagnostics company. Dr. Miller holds a B.S. in Chemistry and Mathematics from Texas A&M University, an M.Phil. in Theoretical Chemistry from University College London and a Ph.D. in Theoretical Chemistry from the University of Oxford.- Thomas Miller自2019年10月共同创立公司以来，一直担任Iambic Therapeutics，Inc.的董事会成员，并自2020年4月起担任Iambic Therapeutics，Inc.的首席执行官。此前，米勒博士曾于2013年2月至2022年3月担任化学教授，并于2008年6月至2013年2月担任加州理工学院化学助理教授。他目前担任基因组诊断公司Veracyte, Inc.的董事。Miller博士拥有得克萨斯农工大学化学和数学学士学位、伦敦大学学院理论化学硕士学位和牛津大学理论化学博士学位。
- Thomas Miller has served as a member of Iambic Therapeutics, Inc.'s board of directors since he co founded the Company in October 2019 and as Iambic Therapeutics, Inc.'s Chief Executive Officer since April 2020. Previously, Dr. Miller was a Professor of chemistry from February 2013 to March 2022 and Assistant Professor of Chemistry from June 2008 to February 2013 at the California Institute of Technology. He currently serves as a director of Veracyte, Inc., a genomic diagnostics company. Dr. Miller holds a B.S. in Chemistry and Mathematics from Texas A&M University, an M.Phil. in Theoretical Chemistry from University College London and a Ph.D. in Theoretical Chemistry from the University of Oxford.
- Frederick Manby
Frederick Manby自2019年10月共同创立公司以来一直担任Iambic Therapeutics，Inc.的董事会成员，并自2020年4月起担任Iambic Therapeutics，Inc.的首席技术官。此前，Manby博士曾于2010年8月至2022年3月在布里斯托大学担任理论化学教授。他拥有约克大学化学学士和博士学位。
Frederick Manby has served as a member of Iambic Therapeutics, Inc.'s board of directors since he co founded the Company in October 2019 and as Iambic Therapeutics, Inc.'s Chief Technology Officer since April 2020. Previously, Dr. Manby was a Professor of Theoretical Chemistry from August 2010 to March 2022 at the University of Bristol. He holds a B.Sc. and Ph.D. in Chemistry from the University of York.- Frederick Manby自2019年10月共同创立公司以来一直担任Iambic Therapeutics，Inc.的董事会成员，并自2020年4月起担任Iambic Therapeutics，Inc.的首席技术官。此前，Manby博士曾于2010年8月至2022年3月在布里斯托大学担任理论化学教授。他拥有约克大学化学学士和博士学位。
- Frederick Manby has served as a member of Iambic Therapeutics, Inc.'s board of directors since he co founded the Company in October 2019 and as Iambic Therapeutics, Inc.'s Chief Technology Officer since April 2020. Previously, Dr. Manby was a Professor of Theoretical Chemistry from August 2010 to March 2022 at the University of Bristol. He holds a B.Sc. and Ph.D. in Chemistry from the University of York.